SEC Form DEF 14A filed by Travelzoo

You are cordially invited to attend the Annual Meeting of Stockholders of Travelzoo on April 20, 2026 at 10 a.m. Eastern Time (ET). Travelzoo will hold its 2026 Annual Meeting in a virtual meeting format only, via webcast. You can access the meeting at:

www.virtualshareholdermeeting.com/TZOO2026

If you encounter any difficulties while accessing the virtual meeting during the check-in or meeting time, a technical assistance phone number will be made available on the virtual meeting registration page 15 minutes prior to the start time of the meeting.

In connection with the meeting, we enclose a notice of the meeting, a proxy statement and a proxy card. This proxy statement or notice thereof is first being mailed or furnished to stockholders on or about March 11, 2026. Detailed information relating to Travelzoo’s activities and operating performance is contained in our 2025 Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 11, 2026, which is also enclosed. We encourage you to read the Form 10-K.

To attend the Annual Meeting of Stockholders and vote, you must be a stockholder of record as of 5:00 p.m. ET on March 5, 2026. You will be able to attend the Annual Meeting as well as vote during the meeting by visiting the link provided above and entering the 16-digit number included in your proxy card.

If you hold your shares in street name through a bank, broker, or other nominee, please have the control number set forth on your proxy card available for admittance to the meeting. You must check in via the meeting link in order to be admitted to the Annual Meeting of Stockholders.

Your vote is important. Whether or not you plan to attend the Annual Meeting of Stockholders, please vote your shares via mail with the enclosed proxy card. Please note that you can attend the virtual meeting and vote, even if you have previously voted by proxy.

Travelzoo will make available an alphabetical list of stockholders entitled to vote at the meeting for examination by any stockholder during ordinary business hours at Travelzoo’s office, located at 590 Madison Avenue, 35^th Floor, New York, NY 10022, U.S.A., for ten days prior to the meeting. A stockholder may examine the list for any legally valid purpose related to the meeting.

On behalf of the entire Board of Directors of Travelzoo, we look forward to seeing you at the meeting.

NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of Travelzoo, a Delaware corporation (“Travelzoo” or the “Company”), will be held on April 20, 2026 at 10 a.m. ET, in a virtual meeting format only, via webcast available at www.virtualshareholdermeeting.com/TZOO2026, for the following purposes:

Only stockholders of record as of 5:00 p.m. ET on March 5, 2026 may vote at the Annual Meeting of Stockholders. Your vote is important. Whether you plan to attend the Annual Meeting or not, please cast your vote by completing, dating and signing the enclosed proxy card and returning it via the methods indicated on the proxy card. If you attend the virtual meeting and prefer to vote at that time, you may do so even if you have previously voted by proxy. Please retain the control number set forth on your proxy card so that we can verify your identity to admit you to the virtual meeting.

Travelzoo’s Board is soliciting proxies to be voted at the 2026 Annual Meeting of Stockholders. This proxy statement includes information about the matters to be voted upon at the meeting.

Only stockholders of record of our common stock, par value $0.01 per share (the “Common Stock”), as of 5:00 p.m. ET on March 5, 2026 (the “Record Date”) will be entitled to notice of, and to vote at, the Annual Meeting. As of the Record Date, there were 10,932,337 shares of our Common Stock issued and outstanding.

The Annual Meeting of Stockholders will take place on April 20, 2026 in a virtual meeting format only at www.virtualshareholdermeeting.com/TZOO2026. The meeting will begin at 10:00 a.m. ET.

To attend the Annual Meeting and vote, you must be a stockholder of record as of 5:00 p.m. ET on March 5, 2026. You will be able to attend the Annual Meeting as well as vote during the meeting by visiting www.virtualshareholdermeeting.com/TZOO2026 and entering the 16-digit number included in your proxy card. If you encounter any difficulties while accessing the virtual meeting during the check-in or meeting time, a technical assistance phone number will be made available on the virtual meeting registration page 15 minutes prior to the start time of the meeting.

Stockholders will vote on five proposals:

Stockholders will further transact such other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.

The Board recommends that you vote your shares “FOR” Proposal 1, Proposal 2, Proposal 3, Proposal 4 and Proposal 5.

Per Travelzoo’s Amended and Restated By-laws, each stockholder is entitled to one (1) vote for each share of Common Stock held which has voting power upon the matter in question. You may hold shares as follows:

Stockholders can vote by proxy (via the Internet or by mail) or in person (at the virtual meeting). Granting a proxy does not in any way affect your right to attend the Annual Meeting and vote.

If you are a stockholder of record, you may vote your proxy by mail or by Internet. To vote by Internet, go to www.proxyvote.com, enter your 16-digit number included on your proxy card and follow the instructions. You can vote by mail by mailing in your proxy card to: c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717, U.S.A.

Note, if you wish to receive a paper or e-mail copy of the materials, you must request one. There is no charge for requesting a copy. Please choose one of the following methods to make your request: (1) by Internet: www.proxyvote.com; (2) by telephone: 1-800-579-1639; or (3) by e-mail: [email protected]. If requesting materials by e-mail, please send a blank e-mail with your 16-digit number included on your proxy card.

If you vote by proxy, the persons named on the card (your “proxies”) will vote your shares in the manner you indicate. You may specify whether your shares should be voted for all, some or none of the nominees for director or any other proposals properly brought before the Annual Meeting. If you sign your proxy card and do not indicate specific choices, your shares will be voted “FOR” the election of all nominees for director and “FOR” Proposal 2, Proposal 3, Proposal 4 and Proposal 5. If any other matter is properly brought before the meeting, your proxies will vote in accordance with the Company’s discretion. At the time of submitting this proxy statement for printing, we know of no matter that will be acted on at the Annual Meeting of Stockholders other than those discussed in this proxy statement.

If you wish to give a proxy to someone other than the persons named on the enclosed proxy card, you may strike out the names appearing on the card and write in the name of any other person, sign the proxy, and deliver it to the person whose name has been substituted.

If you give a proxy, you may revoke it in any one of three ways:

If you are a stockholder of record, you may cast your vote at the virtual Annual Meeting by logging into the webcast available at www.virtualshareholdermeeting.com/TZOO2026.

You can submit voting instructions to your broker or nominee. In most instances, you will be able to do this over the Internet or by mail. Please refer to the voting instruction card included in the materials provided by your broker or nominee. If you wish to vote at the virtual Annual Meeting, please have the control number set forth on your proxy card available for admittance to the virtual meeting.

Each share of our Common Stock is entitled to one (1) vote with respect to each matter on which it is entitled to vote. Pursuant to our Amended and Restated By-laws, our directors are elected by a majority of the votes cast at a meeting of the stockholders by the holders of stock entitled to vote in the election; provided, however, if the Corporate Secretary determines that the number of nominees for director exceeds the number of directors to be elected, directors will be elected by a plurality of the votes of the shares represented in person or by proxy at the meeting. For purposes hereof, a majority of votes cast means that the number of shares voted “for” a nominee must exceed the votes cast “against” such nominee. The following will not be votes cast: (a) a share whose ballot is marked as withheld; (b) a share otherwise present at the meeting but for which there is an abstention; and (c) a share otherwise present at the meeting for which a shareholder gives no authority or direction. The affirmative vote of a majority of the shares of the Company’s Common Stock present in person or represented by proxy and entitled to vote on the proposal will be considered as the approval of Proposal 2, the approval of Proposal 3, the approval of Proposal 4 and, by an advisory vote, the approval of Proposal 5.

In order to have a valid stockholder vote, a stockholder quorum must exist at the Annual Meeting. A quorum will exist when stockholders holding a majority of the outstanding shares of Common Stock are present at the meeting, either in person or by proxy.

Azzurro Capital Inc., whose beneficial owner is Mr. Ralph Bartel, the founder of Travelzoo, holds an aggregate of 3,662,696 shares of our Common Stock, representing approximately 33.5% of the outstanding shares, as of March 5, 2026.

All properly executed proxies delivered pursuant to this solicitation and not revoked will be voted at the Annual Meeting as specified in such proxies. As noted above, if no voting instructions are indicated, proxies will be voted as recommended by our Board on all matters, and in the discretion of the proxy holder on any other matters that properly come before the Annual Meeting.

A broker “non-vote” occurs when a nominee holding shares of Common Stock for the beneficial owner does not vote on a particular proposal because the nominee does not have discretionary voting power with respect to that item and has not received instructions from the beneficial owner. Brokers that have not received voting instructions from their clients cannot vote on their clients’ behalf on “non-routine” proposals. The vote on Proposals 1, 2, 3, 4 and 5 are considered “non-routine”. Broker non-votes will be counted for the purpose of obtaining a quorum for the Annual Meeting but will not have any other effect with respect to Proposals 1, 2, 3, 4 and 5, as shares that constitute broker non-votes are not considered entitled to vote on these non-routine proposals.

Abstentions are counted as “shares present” at the Annual Meeting for purposes of determining the presence of a quorum and with respect to any matters being voted upon at the Annual Meeting. As stated above (at “What vote is required to approve each proposal?”), abstentions will have no effect on the outcome of the election of directors, but with respect to any other proposal an abstention will have the same effect as a vote against such proposal.

We intend to announce preliminary voting results at the Annual Meeting. We will publish the final results in a report on Form 8-K, which we intend to file within four (4) business days following the Annual Meeting. You can obtain a copy of the Form 8-K on Travelzoo’s investor relations website at www.travelzoo.com/ir, by calling the U.S. Securities and Exchange Commission (“SEC”) at (800) SEC-0330 for the location of the nearest public reference room, or through the EDGAR system at www.sec.gov. Information on our website does not constitute part of this proxy statement.

Under Travelzoo’s Amended and Restated By-laws, the number of directors of Travelzoo shall consist of one or more members, the number thereof to be determined from time to time by the Board. For 2026, the Board has determined that the number of directors shall be fixed at five (5). Each director holds office for a term of one (1) year, until the Annual Meeting of Stockholders next succeeding the director’s election and until a successor is elected and qualified or until the earlier resignation or removal of the director. The following individuals have been nominated for election to our Board, each to serve until the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified or until their earlier resignation or removal.

Following is information about each nominee, including biographical data for at least the last five (5) years. Should one or more of these nominees become unavailable to accept nomination or election as a director, the individuals named as proxies on the enclosed proxy card will vote the shares that they represent for the election of such other persons as the Board may recommend, unless the Board reduces the number of directors. We have no reason to believe that any nominee will be unable or unwilling to serve if elected as a director.

The ages, principal occupations, directorships held and other information as of March 5, 2026, with respect to our nominees are described below.

Each of the director nominees listed above, other than Mr. Ralph Bartel, is currently a director of Travelzoo and was previously elected by the shareholders. Ms. Christina Sindoni Ciocca, Mr. Volodymyr Cherevko, Mr. Michael Karg and Ms. Sharry Sun were elected directors of Travelzoo at the Company’s Annual Meeting of Stockholders held on June 4, 2025. Mr. Holger Bartel and Ms. Carrie Liqun Liu will not stand for re-election at the Annual Meeting, as the Nominating and Corporate Governance Committee recommended that Mr. Ralph Bartel should replace Mr. Holger Bartel and Ms. Carrie Liqun Liu should rotate off due to her tenure on the Board, in line with corporate governance best practices. The independent directors will be appointed to the various committees (Compensation, Audit and Nominating and Corporate Governance) and the directors will be appointed to the various positions (Chair) by the Board following their election at the Annual Meeting.

Our Board has determined that each of Mr. Cherevko, Mr. Karg and Ms. Sun meet the independence requirements of the listing standards of the NASDAQ Stock Market (“NASDAQ”). Certain affiliates and subsidiaries of the WPP Group, Mr. Karg’s current employer, have from time-to-time represented clients of Travelzoo and purchased media on behalf of such clients from Travelzoo, primarily in the United States; provided, that the Board determined that any amounts paid by any member of the WPP Group to Travelzoo or by Travelzoo to any member of the WPP Group over the past three years are not material. Such relationships and amounts will continue to be monitored going forward. Mr. Karg also confirmed that in his role as Chief Executive Officer for Europe of WPP Media, he is focused only on continental Europe (excluding the United Kingdom). To date, no Travelzoo media purchases have been made by WPP Group on behalf of any client located in continental Europe. The Board therefore determined that no conflict of interest exists pursuant to the Company’s Code of Ethics.

Ms. Sun was previously employed by Travelzoo as the Global Head of Brand until May 2020. Under the rules of NASDAQ, a director who was formerly employed by a company is deemed to be independent three years after having ceased to serve in such capacity. The Board therefore determined that no conflict of interest exists pursuant to NASDAQ listing rules and the Company’s Code of Ethics.

The Board determined that Mr. Ralph Bartel is not independent under the rules of NASDAQ because he is the brother of Mr. Holger Bartel, the Company’s Global Chief Executive Officer and, since January 1, 2023, has served as a consultant for the Company. The Board determined that Ms. Christina Sindoni Ciocca is not independent under the rules of NASDAQ because she is an employee of the Company.

Ralph Bartel, Ph.D., Ph.D., founded Travelzoo in 1998. He was a member of Travelzoo’s Board from May 1998 until December 2022 and served as Chairman of the Board from May 2017 until December 2022. From May 1998 to September 2008, he was the Chairman of the Board and the Chief Executive Officer. From October 2008 to June 2010, he was the Chairman of the Board. He has been a consultant for the Company since January 1, 2023. Mr. Ralph Bartel is a professionally trained journalist who holds a Ph.D. in Communications from the University of Mainz, Germany, a master’s degree in journalism from the University of Eichstätt-Ingolstadt, Germany, a Ph.D. in economics from the University of St. Gallen, Switzerland and an MBA in finance and accounting from the University of St. Gallen, Switzerland. He is the brother of Holger Bartel, Travelzoo’s Global Chief Executive Officer.

Areas of Mr. Ralph Bartel’s relevant experience include media, journalism, Internet, finance and start-up experience.

Christina Sindoni Ciocca has been a member of Travelzoo’s Board since May 2019 and, since December 2022, has been serving as the Chair of the Board. She has been Chief Membership Officer and General Counsel for Travelzoo since January 2026 and CEO of Jack’s Flight Club since September 2022. She was previously General Counsel and Head of Global Functions since April 2022, General Counsel since June 2019, and Counsel since April 2018. Prior to joining Travelzoo, Ms. Ciocca was an attorney at Sidley Austin LLP, practicing in mergers & acquisitions in both Chicago, IL and New York, NY, from September 2014 to March 2018. Ms. Ciocca earned her juris doctor degree from the Law School of the University of Notre Dame and a Bachelor of Science in Economics degree from the Wharton School of the University of Pennsylvania, with concentrations in marketing and operations & information management. Prior to law school, Ms. Ciocca worked in digital marketing, including for American Express.

Areas of Ms. Ciocca’s relevant experience include corporate governance, law, mergers & acquisitions and marketing.

Michael Karg, Ph.D. has been a member of Travelzoo’s Board since May 2022. He is the Chief Executive Officer for Europe of WPP Media and has been since April 2025. Before that he was the Global Chief Operating Officer of Mindshare since November 2021. From January 2016 to December 2019, Mr. Karg was the Group Chief Executive Officer of Ebiquity plc, a company listed on the London stock exchange (AIM). From May 2013 to December 2015, he was the Chief Executive Officer International of Razorfish. From September 2011 to May 2013, Mr. Karg was the President EMEA for Razorfish and Digitas International in Paris. From September 2010 to May 2013, he was also the Chief Operating Officer of Razorfish and Digitas International. From 2013 to 2017, Mr. Karg served as a member of the board of directors of Travelzoo. Mr. Karg holds a Ph.D. in management and a master’s equivalent in finance and accounting from the University of St. Gallen, Switzerland.

Areas of Mr. Karg’s relevant experience include digital media and global operations.

Volodymyr Cherevko has been a member of Travelzoo’s Board since May 2022. He has expertise in marketing, product development, strategy and business transformation developed over 20 years with Fortune 500 companies, such as Procter & Gamble, PepsiCo, Whirlpool and Haier. Currently, Mr. Cherevko is the Europe Region CEO and General Manager of PRÆSIDIAD and has been since November 2025. Before that, he was President of Alteva Enterprises since February 2024 and Chief Transformation Officer of Haier Europe since August 2021. Between November 2017 and August 2021, he was the General

Areas of Mr. Cherevko’s relevant experience include marketing, product development, strategy and business transformation.

Sharry Sun has been a member of Travelzoo’s board since June 2025. Ms. Sun is the Chief Executive Officer of Greater China, Head of DTC Business Asia and a board member of Frette China, and has been since August 2024. Before that, Ms. Sun was the Vice President of Strategy, Insight and Analytics, Incubation and Innovation Investment for Tapestry in Asia since August 2022. Between November 2020 and December 2021, she was the

Chief Marketing Officer for Europe North Region of Michelin. Ms. Sun previously served as the Global Head of Brand for Travelzoo between May 2018 and May 2020. Ms. Sun holds a master’s degree in business development from Tongji University in Shanghai, a joint diploma in business administration and management from WHU – Otto Beisheim School of Management in Germany under exchange program and a bachelor’s degree in business administration from the South China University of Technology in Guangzhou.

Areas of Ms. Sun’s relevant experience include business administration, investment management, strategy, consumer understanding and branding.

On March 9, 2023, the SEC instituted cease-and-desist proceedings against Mr. Ralph Bartel in connection with alleged violations of the beneficial ownership reporting requirements under the Securities Exchange Act of 1934 arising out of Mr. Ralph Bartel’s beneficial share ownership in Wilhelmina International, Inc. Without admitting or denying the SEC’s findings, Mr. Ralph Bartel submitted an offer of settlement in which he agreed to cease and desist from future violations and pay a penalty. The SEC accepted the offer of settlement. There is no restriction on Mr. Ralph Bartel’s ability to serve as an officer or director on the Board.

Our Certificate of Incorporation, as amended, does not authorize cumulative voting. Delaware law and our Amended and Restated By-laws provide that directors are to be elected by a majority of the votes cast at the Annual Meeting by the holders of stock entitled to vote on the election of directors; provided, however, that, if the Corporate Secretary determines that the number of nominees for director exceeds the number of directors to be elected, directors shall be elected by a plurality of the votes of the shares represented in person or by proxy at any meeting of stockholders held to elect directors and entitled to vote on such election of directors. A majority of the votes cast means that the number of shares voted “for” a nominee must exceed the votes cast “against” such nominee’s election. The following shall not be votes cast: (a) a share whose ballot is marked as withheld; (b) a share otherwise present at the meeting but for which there is an abstention; and (c) a share otherwise present at the meeting for which a shareholder gives no authority or direction. Thus, abstentions and broker non-votes will have no effect on the election of directors (other than the fact that they are counted for the purpose of determining whether a stockholder quorum exists at the Annual Meeting). Proxies cannot be voted for a greater number of persons than the number of nominees named.

The Board believes that each director nominee possesses the qualities and experience a member of Travelzoo’s Board should possess. The Board seeks out, and the Board comprises, individuals whose background and experience complement those of other Board members.

THE BOARD RECOMMENDS THAT STOCKHOLDERS VOTE “FOR” THE ELECTION OF THE FIVE DIRECTOR NOMINEES NAMED ABOVE.

The Board has appointed an Audit Committee, a Compensation Committee, a Disclosure Committee and a Nominating and Corporate Governance Committee. Below is a table indicating the membership of each committee and how many times the Board and each such committee met in fiscal year 2025. Beginning in 2021, the Board voted to change membership in the Disclosure Committee to management only in line with corporate governance best practices. Other than Ms. Carrie Liqun Liu, each Board member attended at least 75 percent of the total number of meetings of the Board and of the committees on which he or she served.

The Company does not require that directors attend the Annual Meeting of Stockholders. Ms. Ciocca serves as Chair of the Board of Directors. Mr. Karg serves as the Chair of the Audit Committee and Mr. Cherevko serves as the Chair of the Compensation Committee and Nominating and Corporate Governance Committee.

The Audit Committee is appointed by the Board to discharge the Board’s responsibilities with respect to among other things, (i) the Company’s accounting and financial reporting processes; (ii) audits of the financial statements of the Company; and (iii) the qualifications, independence and performance of the Company’s independent auditors. A complete description of the Audit Committee’s responsibilities is set forth in its written charter. A copy of the Amended and Restated Audit Committee Charter, which was adopted by the Board on March 22, 2019, can be found in Appendix A of our 2019 proxy statement. The Audit Committee is responsible for appointing an independent registered public accounting firm and is directly responsible for the compensation and oversight of the work of our independent registered public accounting firm. The Audit Committee is composed solely of independent directors as defined in the listing standards of the NASDAQ Stock Market, the SEC, the Sarbanes-Oxley Act of 2002 and any successor rules or regulations. The Board determined that Mr. Michael Karg qualifies as an audit committee financial expert within the meaning of SEC regulations.

The Compensation Committee is appointed by the Board to discharge the Board’s responsibilities with respect to, among other things, the evaluation, approval and administration of the Company’s compensation and incentive plans, policies and programs for executive officers and directors of the Company. A complete description of the Compensation Committee’s responsibilities is set forth in its written charter. A copy of the Compensation Committee Charter, which was adopted by the Board on March 22, 2019, can be found in Appendix B of our 2019 proxy statement.

The Disclosure Committee’s primary responsibilities are (i) to design, establish and evaluate controls and other procedures that are designed to ensure the accuracy and timely disclosure of information to the SEC and investment community and (ii) to review and supervise preparation of SEC filings, press releases and other broadly disseminated correspondence. Originally, the Disclosure Committee included two members of the Board, but at the Q1 2021 Board meeting, the directors voted to change the Disclosure Committee to a management committee, reporting directly to the Global Chief Executive Officer and Chief Accounting Officer or Chief Financial Officer, as applicable, and providing updates to the Audit Committee as necessary, in line with corporate governance best practices.

The Nominating and Corporate Governance Committee assists the Board in identifying qualified individuals to become directors, makes recommendations to the Board concerning the size, structure and composition of the Board and its committees, monitors the process to assess the Board’s effectiveness and is primarily responsible for oversight of corporate governance. In evaluating potential nominees to the Board, the Nominating and Corporate Governance Committee considers, among other things, independence, character, ability to exercise sound judgment, age, demonstrated leadership, skills, including financial literacy, and experience in the context of the needs of the Board. The Nominating and Corporate Governance Committee considers candidates proposed by shareholders and evaluates them using the same criteria as for other candidates. The Nominating and Corporate Governance Committee recommended to the full Board each of the current nominees for election to the Board.

The full Board oversees enterprise risk as part of its role in reviewing and overseeing the implementation of the Company’s strategic plans and objectives. The risk oversight function is administered both in full Board discussions, informal meetings and in individual committees that are tasked by the Board with oversight of specific risks. On a regular basis, the Board and its committees receive information and reports from management on the status of the Company and the risks associated with the Company’s strategy and business plans. In addition, the Audit Committee reviews the Company’s risk assessment and risk management policies and procedures at least annually, including steps taken to monitor and control such exposures. The Board believes the continuity of Board membership and the independent directors constituting a majority of the Board encourage open discussion and assessment of the Company’s ability to manage its risks. For more information on how the Board oversees cybersecurity-related risks, please review the Company’s Annual Report on Form 10-K, filed March 11, 2026, which is incorporated herein by reference.

The Company has adopted an Insider Trading Policy that governs the purchase, sale, and/or dispositions of the Company’s securities by directors, officers, and employees and is reasonably designed to promote compliance with insider trading laws, rules, and regulations, and any listing standards applicable to the Company. The Company’s Insider Trading Policy is filed as an exhibit to our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

We have adopted a Code of Ethics that applies to our executive officers, including, but not limited to our Global Chief Executive Officer, Chief Membership Officer and General Counsel, and our Chief Accounting Officer. This Code of Ethics is posted on our website located at www.travelzoo.com/blog/code-ethics. A copy of the Code of Ethics is also available in print to stockholders and interested parties without charge upon written request delivered to our Corporate Secretary at Travelzoo, 590 Madison Avenue, 35^th Floor, New York, NY 10022.

The Board has established a process to receive communications from stockholders. Stockholders and other interested parties may contact any member (or all members) of the Board, or the non-management directors as a group, any Board committee or any chair of any such committee by mail. To communicate with the Board, any individual director or any group or committee of directors, correspondence should be addressed to the Board or any such individual director or group or committee of directors by either name or title. All such correspondence should be sent to “c/o Corporate Secretary” at Travelzoo, 590 Madison Avenue, 35^th Floor, New York, NY 10022.

All communications received as set forth in the preceding paragraph will be opened by the Corporate Secretary for the sole purpose of determining whether the contents represent a message to our directors. Any contents that are not in the nature of advertising, promotions of a product or service, patently offensive material or matters deemed inappropriate for the Board will be forwarded promptly to the addressee. In the case of communications to the Board or any group or committee of directors, the Corporate Secretary will make sufficient copies of the contents to send to each director who is a member of the group or committee to which the correspondence is addressed.

Directors of the Company or its subsidiaries are entitled to receive certain retainers and fees as determined by the Board based on recommendations of the Compensation Committee. In 2025, the Compensation Committee recommended a 3% inflationary increase to all Board fees (in line with the standard increases provided to employees of the Company), effective April 1, 2025. The retainers and meeting fees are as follows:

Members of the Board may receive fees for additional meetings and committee work and may receive stock option grants on an ad hoc basis at the discretion of the Compensation Committee.

We reimburse directors for out-of-pocket expenses incurred in connection with attending meetings. In November 2025, the directors had one in-person Board meeting at the same time as the Global Company Meeting in Cannes, France.

Employees generally do not receive compensation for their services as directors. Accordingly, Ms. Christina Sindoni Ciocca and Mr. Holger Bartel did not receive any compensation for their service as members of the Board in 2025.

The following table shows the fees earned or paid in cash for Travelzoo’s directors for the fiscal year ended December 31, 2025.

The Company maintains policies and procedures to ensure that our directors, executive officers and employees avoid conflicts of interest. Our executive officers, including our Global Chief Executive Officer, Chief Membership Officer and General Counsel and Chief Accounting Officer, are subject to our Code of Ethics. Our Code of Ethics requires our leadership to act with honesty and integrity, and to fully disclose to the Audit Committee any material transaction that reasonably could be expected to give rise to an actual or apparent conflict of interest. The Audit Committee Charter assigns authority for the review of related party transactions to the Audit Committee. In September 2024, the Board unanimously approved the adoption of a related party transactions policy (the “Related Party Transactions Policy”), applicable to directors, officers and employees of the Company, as well as their immediate family members, which enhanced our previously existing procedures. “Related Party Transaction” is defined under the policy as any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, (a) in which (i) Travelzoo or any of its subsidiaries is or will be a participant, (ii) any Related Party has or will have a direct or indirect material interest, (iii) the aggregate amount involved exceeds or may be expected to exceed $120,000 in any fiscal year, and

(b) that would need to be disclosed under Item 404(a) of Regulation S-K. “Related Party” is defined under the policy as members of the Board (including director nominees), named executive officers, any person or entity known by the Company to be a beneficial owner of more than 5% of Travelzoo’s common stock, or any person known by the Company to be an immediate family member of any of the foregoing. The Related Party Transactions Policy requires that Related Parties notify the Chief Membership Officer and General Counsel and obtain the prior approval of the Audit Committee before proceeding with or engaging in any Related Party Transaction. Moreover, employees are required to read and comply with our Guide to Business Conduct, which is a communication to all employees that ensures they are aware of their responsibility to avoid any conflicts of interest or potential conflicts of interest and to make appropriate disclosures to their manager or other personnel.

Our Chief Membership Officer and General Counsel reviews all Related Party Transactions and reports them to the Audit Committee, together with a summary of the material facts, for consideration at a meeting of the Audit Committee, if necessary.

Upon submission to the Audit Committee, the committee will conduct an initial review of all relevant facts and circumstances surrounding each Related Party Transaction. Following the initial review, should the Audit Committee believe pursuing the transaction further would be in the best interests of the Company, the Audit Committee will determine the appropriate process for reviewing and negotiating the Related Party Transaction, including potentially appointing a Special Committee, if necessary. The Audit Committee or Special Committee, if appointed, will work closely with any authorized officers of the Company to negotiate the terms of the transaction and once the process and negotiations have concluded, will provide either approval or disapproval of the entry into such transaction. The Audit Committee (or any appointed Special Committee) may approve the Related Party Transaction only if it determines in good faith that, under all of the circumstances, the transaction is in the best interests of the Company and its shareholders. If the Company becomes aware of a Related Party Transaction that has not been approved under the Related Party Transactions Policy, the Audit Committee may ratify such transaction or direct additional actions, such as immediate discontinuation, rescission or modification of the transaction.

If a Related Party Transaction is ongoing, the Audit Committee may establish guidelines for the Company’s management to follow in its ongoing dealings with the Related Party. Thereafter, the Audit Committee, on at least an annual basis, shall review and assess ongoing relationships with the Related Party to ensure that they follow Travelzoo’s Board of Directors’ guidelines and that the Related Party Transaction remains appropriate.

Related Party Transactions must also comply with the Company’s existing policies and procedures, including, without limitation, the Company’s Guide to Business Conduct, Code of Ethics and Insider Trading Policy.

Ralph Bartel, who founded Travelzoo and who was previously a director of the Company, is the sole beneficiary of the Ralph Bartel 2005 Trust, which is the controlling shareholder of Azzurro Capital Inc. As of March 5, 2026, Azzurro Capital Inc. is the Company’s largest stockholder, holding approximately 33.5% of the Company’s outstanding shares.

Ralph Bartel, founder of Travelzoo, and Holger Bartel, Global Chief Executive Officer, are brothers. Except for Holger Bartel and Ralph Bartel, there are no familial relationships among any of our officers and directors.

To our knowledge, during the last ten years, none of our directors and executive officers have: (i) had a bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; (ii) been convicted in a criminal proceeding or been subject to a pending criminal proceeding, excluding traffic violations and other minor offenses; (iii) been subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his or her involvement in any type of business, securities or banking activities; (iv) been found by a court of competent jurisdiction (in a civil action), the SEC, or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated; or (v) been the subject to, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization, any registered entity, or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

The following table sets forth certain information with respect to the named executive officers of Travelzoo, as determined by the Compensation Committee, as of March 5, 2026.

Holger Bartel, Ph.D., has been Travelzoo’s Global Chief Executive Officer since January 2016 and since October 2023, also serves as Travelzoo’s Head of Strategy. He has been a member of Travelzoo’s Board since June 2023. From July 2010 to May 2017, he was the Chairman of the Board. From October 2011 to October 2013, he was the Head of Strategy. From October 2008 to June 2010, he was Travelzoo’s Chief Executive Officer. From September 1999 to November 2007, he was Executive Vice President. From 1995 to 1998, he was Engagement Manager at McKinsey & Company, a global management consulting firm. From 1992 to 1994, he was a research fellow at Harvard Business School. Mr. Holger Bartel holds a Ph.D. in economics and an MBA in finance and accounting from the University of St. Gallen, Switzerland. He is the brother of Ralph Bartel, the founder of Travelzoo.

Christina Sindoni Ciocca has been with Travelzoo since April 2018. She has been a member of Travelzoo’s Board since May 2019 and, since December 2022, has been serving as the Chair of the Board. She has been Chief Membership Officer and General Counsel for Travelzoo since January 2026 and CEO of Jack’s Flight Club since September 2022. She was previously General Counsel and Head of Global Functions since April 2022, General Counsel since June 2019 and Counsel since April 2018. Prior to joining Travelzoo, Ms. Ciocca was an attorney at Sidley Austin LLP, practicing in mergers & acquisitions in both Chicago, IL and New York, NY, from September 2014 to March 2018. Ms. Ciocca earned her juris doctor degree from the Law School of the University of Notre Dame and a Bachelor of Science in Economics degree from the Wharton School of the University of Pennsylvania, with concentrations in marketing and operations & information management. Prior to law school, Ms. Ciocca worked in digital marketing, including for American Express.

Lijun Qi has been with Travelzoo since December 2016. She has been Chief Accounting Officer for Travelzoo since September 2024 and Finance Director since December 2016. Ms. Qi has been serving as the Company’s principal accounting officer since April 2023. Prior to joining Travelzoo, Ms. Qi was Director, SEC Reporting and Technical Accounting, for InvenSense Inc., a consumer electronics company. Ms. Qi holds a master’s degree in accounting from Widener University, Pennsylvania. Ms. Qi commenced short-term disability leave on March 3, 2025 and long-term disability leave on June 1, 2025.

The Company entered into a Nonqualified Stock Option Agreement (the “HB Option Agreement”) with Mr. Holger Bartel, Global Chief Executive Officer, on February 19, 2026, pursuant to which the Company granted Mr. Bartel the option to purchase 600,000 shares of the Company’s common stock (such option being hereinafter referred to as the “HB Option”). The first tranche of the HB Option shall vest on June 30, 2026 and will not be exercisable unless and until the stockholders approve. Stockholders are being asked to approve the issuance of Common Stock which is issuable to Mr. Bartel upon exercise of the HB Option.

The principal terms of the HB Option Agreement are summarized below. The following summary is qualified in its entirety by the full text of the HB Option Agreement, which is incorporated by reference herein by reference to Appendix A to this proxy statement.

The Compensation Committee engaged an independent compensation consultant, Compensia, to advise on Mr. Bartel’s compensation package, including base salary, bonus, if applicable, and option grant. The Compensation Committee, which is comprised solely of independent directors, unanimously approved the HB Option and the HB Option Agreement, after confirming that Mr. Bartel’s base salary, bonus, option grant, total cash and total compensation for 2025 aligned with the peer group analysis, discussed in further detail in the Executive Compensation section.

The exercise price of the HB Option will be $5.05, which was the NASDAQ closing stock price on February 19, 2026. The HB Option will become exercisable in accordance with the following schedule:

Mr. Bartel must exercise the HB Option by February 19, 2031; after such date, the HB Option will expire.

Mr. Bartel may exercise, in whole or in part, the HB Option by delivering to the Company (a) not less than thirty (30) days prior to the exercise date (or such shorter period as the Company may approve) a written notice (email being acceptable) of intent to exercise and estimated date of exercise and (b) not less than five (5) business days prior to the date of exercise (or such shorter period as the Company may approve) (i) written notice of exercise, designating the number of shares to be purchased, and (ii) payment of the full amount of the purchase price of the shares being purchased and payment of the full amount of applicable taxes triggered by the exercise of the option and shares being purchased.

The HB Option may not be exercised if shareholder approval is not received and may not be exercised prior to the registration of the shares being offered under the HB Option Agreement, which registration shall be filed by the Company with the SEC following the Company’s annual shareholder meeting, so long as approval has been obtained.

As is customary in stock option agreements of this nature, the number of shares subject to the HB Option and exercise price are subject to adjustment in the event there is any change in the number of shares of outstanding common stock of the Company by reason of a stock dividend, recapitalization, merger, consolidation, split-up, combination, exchange of shares or other similar event.

The HB Option is not transferable by Mr. Bartel, other than to a family member or entity owned or controlled by a family member and by will or the laws of descent and distribution. “Family members” includes spouse, parents, children, siblings, mothers and fathers-in-law, sons and daughters-in-law, brothers and sisters-in-law.

Additionally, “family members” include anyone (other than domestic employees) who share such person’s home. The HB Option may be exercised during Mr. Bartel’s lifetime only by his valid transferee in accordance with the terms of the HB Option Agreement or his guardian or legal representative.

If Mr. Bartel’s employment with the Company is terminated, including in the event of his death or disability, any portion of the HB Option which is not then exercisable will immediately terminate. With respect to any portion of the HB Option which is then exercisable on the date of termination of employment, Mr. Bartel (or, in the event of his death, his legatee(s) under his last will, or his personal representatives or distributes, or, in the event of a transfer in accordance with the terms of the HB Option Agreement, his transferee) may exercise such portion of the HB Option for a period of ninety (90) days following such termination, but in no event after February 19, 2031. For the avoidance of doubt, an amendment of Mr. Bartel’s employment agreement or employment relationship shall not constitute a termination of employment.

Mr. Holger Bartel is Travelzoo’s Global Chief Executive Officer.

THE COMPENSATION COMMITTEE ON BEHALF OF THE BOARD UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE APPROVAL OF THIS PROPOSAL RELATING TO THE HB OPTION AGREEMENT.

The Company entered into a Nonqualified Stock Option Agreement (the “JB Option Agreement”) with Mr. Jason Bushman, General Manager, U.S., on December 30, 2025, pursuant to which the Company granted Mr. Bushman the option to purchase 50,000 shares of the Company’s common stock (such option being hereinafter referred to as the “JB Option”). The first tranche of the JB Option shall vest on September 1, 2026 and will not be exercisable unless and until the stockholders approve. Stockholders are being asked to approve the issuance of Common Stock which is issuable to Mr. Bushman upon exercise of the JB Option.

The principal terms of the JB Option Agreement are summarized below. The following summary is qualified in its entirety by the full text of the JB Option Agreement, which is incorporated by reference herein by reference to Appendix B to this proxy statement.

The exercise price of the JB Option will be $7.14, which was the NASDAQ closing stock price on December 29, 2025. The JB Option will become exercisable in accordance with the following schedule:

Mr. Bushman must exercise the JB Option by December 29, 2030; after such date, the JB Option will expire.

Mr. Bushman may exercise, in whole or in part, the JB Option by delivering to the Company (a) not less than thirty (30) days prior to the exercise date (or such shorter period as the Company may approve) a written notice (email being acceptable) of intent to exercise and estimated date of exercise and (b) not less than five (5) business days prior to the date of exercise (or such shorter period as the Company may approve) (i) written notice of exercise, designating the number of shares to be purchased, and (ii) payment of the full amount of the purchase price of the shares being purchased and payment of the full amount of applicable taxes triggered by the exercise of the option and shares being purchased.

The JB Option may not be exercised if shareholder approval is not received and may not be exercised prior to the registration of the shares being offered under the JB Option Agreement, which registration shall be filed by the Company with the SEC following the Company’s annual shareholder meeting, so long as approval has been obtained.

As is customary in stock option agreements of this nature, the number of shares subject to the JB Option and exercise price are subject to adjustment in the event there is any change in the number of shares of outstanding common stock of the Company by reason of a stock dividend, recapitalization, merger, consolidation, split-up, combination, exchange of shares or other similar event.

The JB Option is not transferable by Mr. Bushman, other than pursuant to will or the laws of descent and distribution.

The JB Option may be exercised during Mr. Bushman’s lifetime only by his valid transferee in accordance with the terms of the JB Option Agreement or his guardian or legal representative.

If Mr. Bushman’s employment with the Company is terminated, including in the event of his death or disability, any portion of the JB Option which is not then exercisable will immediately terminate. With respect to any portion of the JB Option which is then exercisable on the date of termination of employment, Mr. Bushman (or, in the event of his death, his legatee(s) under his last will, or his personal representatives or distributes, or, in the event of a transfer in accordance with the terms of the JB Option Agreement, his transferee) may exercise such portion of the JB Option for a period of ninety (90) days following such termination, but in no event after December 29, 2030. For the avoidance of doubt, an amendment of Mr. Bushman’s employment agreement or employment relationship shall not constitute a termination of employment.

Mr. Jason Bushman is Travelzoo’s General Manager, U.S.

THE COMPENSATION COMMITTEE ON BEHALF OF THE BOARD UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE APPROVAL OF THIS PROPOSAL RELATING TO THE JB OPTION AGREEMENT.

The Company entered into a Nonqualified Stock Option Agreement (the “AH Option Agreement”) with Ms. Azar Hashemi, Head of Engineering, on March 4, 2026, pursuant to which the Company granted Ms. Hashemi the option to purchase 50,000 shares of the Company’s common stock (such option being hereinafter referred to as the “AH Option”). The first tranche of the AH Option shall vest on March 4, 2027 and will not be exercisable unless and until the stockholders approve. Stockholders are being asked to approve the issuance of Common Stock which is issuable to Ms. Hashemi upon exercise of the AH Option.

The principal terms of the AH Option Agreement are summarized below. The following summary is qualified in its entirety by the full text of the AH Option Agreement, which is incorporated by reference herein by reference to Appendix C to this proxy statement.

The exercise price of the AH Option will be $6.28, which was the NASDAQ closing stock price on March 4, 2026. The AH Option will become exercisable in accordance with the following schedule:

Ms. Hashemi must exercise the AH Option by March 4, 2031; after such date, the AH Option will expire.

Ms. Hashemi may exercise, in whole or in part, the AH Option by delivering to the Company (a) not less than thirty (30) days prior to the exercise date (or such shorter period as the Company may approve) a written notice (email being acceptable) of intent to exercise and estimated date of exercise and (b) not less than five (5) business days prior to the date of exercise (or such shorter period as the Company may approve) (i) written notice of exercise, designating the number of shares to be purchased, and (ii) payment of the full amount of the purchase price of the shares being purchased and payment of the full amount of applicable taxes triggered by the exercise of the option and shares being purchased.

The AH Option may not be exercised if shareholder approval is not received and may not be exercised prior to the registration of the shares being offered under the AH Option Agreement, which registration shall be filed by the Company with the SEC following the Company’s annual shareholder meeting, so long as approval has been obtained.

As is customary in stock option agreements of this nature, the number of shares subject to the AH Option and exercise price are subject to adjustment in the event there is any change in the number of shares of outstanding common stock of the Company by reason of a stock dividend, recapitalization, merger, consolidation, split-up, combination, exchange of shares or other similar event.

The AH Option is not transferable by Ms. Hashemi, other than pursuant to will or the laws of descent and distribution.

The AH Option may be exercised during Ms. Hashemi’s lifetime only by her valid transferee in accordance with the terms of the AH Option Agreement or her guardian or legal representative.

If Ms. Hashemi’s employment with the Company is terminated, including in the event of her death or disability, any portion of the AH Option which is not then exercisable will immediately terminate. With respect to any portion of the AH Option which is then exercisable on the date of termination of employment, Ms. Hashemi (or, in the event

of her death, her legatee(s) under her last will, or her personal representatives or distributes, or, in the event of a transfer in accordance with the terms of the AH Option Agreement, her transferee) may exercise such portion of the AH Option for a period of ninety (90) days following such termination, but in no event after March 4, 2031. For the avoidance of doubt, an amendment of Ms. Hashemi’s employment agreement or employment relationship shall not constitute a termination of employment.

Ms. Azar Hashemi is Travelzoo’s Head of Engineering.

THE COMPENSATION COMMITTEE ON BEHALF OF THE BOARD UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE APPROVAL OF THIS PROPOSAL RELATING TO THE AH OPTION AGREEMENT.

Section 14A of the Exchange Act requires that we include in this proxy statement a non-binding stockholder vote on our executive compensation as described herein (commonly referred to as “Say-on-Pay”).

The design of our executive compensation program is not a mechanical process, and our Board uses its judgment and experience and works with our Compensation Committee to determine the appropriate mix of compensation for each executive. Additionally, the Compensation Committee has engaged an independent compensation consultant, Compensia, to advise on executive compensation. Please read the Executive Compensation section for additional details.

The Board of Directors and the Compensation Committee strongly endorse the Company’s executive compensation program and unanimously recommend that stockholders vote in favor of the following resolution:

Because the vote is advisory, it will not be binding upon the Board or the Compensation Committee and neither the Board nor the Compensation Committee will be required to take any action as a result of the outcome of the vote on this proposal. The Compensation Committee will consider the outcome of the vote when considering future executive compensation arrangements. The affirmative vote of the majority of the shares of the Company’s Common Stock present in person or represented by proxy and entitled to vote on the proposal will be considered as the approval, by an advisory vote, of the compensation of our named executive officers.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE APPROVAL OF THE ADVISORY RESOLUTION RELATING TO THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

The following Executive Compensation discussion describes our overall compensation philosophy and the primary components of our compensation program. Furthermore, the Executive Compensation discussion explains the process by which the Compensation Committee, or “Committee”, determined the 2025 compensation for our Global Chief Executive Officer, General Counsel and Head of Global Functions (now Chief Membership Officer and General Counsel), and Chief Accounting Officer. We refer to these individuals collectively as the “named executives” or the “named executive officers”.

The fundamental objectives of our executive compensation program are to attract and retain highly qualified executive officers, motivate these executive officers to materially contribute to our long-term business success, and align the interests of our executive officers and stockholders by rewarding our executives for individual and corporate performance based on qualitative and quantitative targets established by the Committee.

We believe that achievement of these compensation program objectives enhances long-term profitability and stockholder value. Although we consider several factors in our pay decisions, the elements utilized to guide the Committee to help it achieve its objectives include the following:

We implement our compensation philosophy through setting base salaries for our executive officers based on market research, including peer analyses provided by an independent compensation consultant, providing bonus opportunities when appropriate for the executive’s role, with such bonuses containing performance-based targets as applicable, granting stock options to certain key employees when appropriate and reviewing and approving other terms of employment agreements as needed and as appropriate. Given the Company’s current size, we are mindful of and review with our compensation consultant several metrics to ensure that our compensation is in line with peers and competitive to attract the best talent.

This methodology is reviewed annually by the Committee and updated as needed to align with the goals of the business.

Compensation Committee Members. The Committee is responsible for establishing, overseeing and reviewing executive compensation policies and for approving, validating and benchmarking the compensation and benefits for named executive officers. The Committee is also responsible for determining the fees paid to our outside directors. The Committee included Mr. Volodymyr Cherevko, Mr. Michael Karg and Ms. Sharry Sun. Mr. Cherevko, Mr. Karg and Ms. Sun satisfied the independence requirements of NASDAQ.

Independent Compensation Consultant. The Committee engaged an independent compensation consultant, Compensia, to assist in its review of executive compensation for the Global Chief Executive Officer, Chief Membership Officer and General Counsel and Chief Accounting Officer (as well as outside director compensation).

The Company worked closely with Compensia to build an 15-company peer group, which included companies from the same Global Industry Classification Standard (GICS) industry classification as the Company (specifically, 502030 Interactive Media & Services), as well as companies from other GICS industry classifications such as Interactive Media & Services, Movies & Entertainment, Interactive Home Entertainment, Broadline Retail, Hotels, Resorts & Cruise Lines, Apparel Retail and Application Software, that are within a range of similar revenues, market capitalizations, profitability, etc. (i.e., of a similar size). This peer group has been reviewed and adjusted each year as needed. The Committee considered when initially compiling this peer group how this peer group is different than the peer group built by Institutional Shareholder Services (ISS), which focuses on peers that are comparable in terms of size and industry (meaning companies in the peer group built by ISS are typically all from the same GICS industry classification), and confirmed that any discrepancies to the ISS peer group were warranted. Specifically, the Committee felt the peer group built by Compensia, which covers various industries, aligns better with the Company’s varied business model of advertising/media, voucher sales, hotel platform, entertainment and membership, which results in the Company being able to be classified in a mix of industries instead of falling within just one. The Committee therefore gave considerable weight to the market data from the peer group in determining compensation levels for its executive officers for 2025 and 2026, ensuring that each component, as well as the overall package, fell in or around the median, given the Company’s smaller size relative to its peers.

Role of Management. During 2025, the Committee engaged in its annual review of executive compensation with the goal of ensuring the appropriate combination of fixed and variable compensation linked to individual and corporate performance. In the course of its review, the Committee considered (a) the advice and input of the Company’s Human Resources Director, Global Chief Executive Officer, Chief Membership Officer and General Counsel and Founder; (b) data prepared by management, including historical compensation and promotions; and (c) data prepared by the independent compensation consultant, as outlined above. Management and the consultant assisted the Committee to properly evaluate employee performance, establish business performance targets, goals and objectives and recommend salary and bonus levels. While executive officers provided feedback relating to their own compensation for the Committee to consider, the Committee held sessions without the executives present, as necessary, to finalize the compensation.

The Committee has structured an executive compensation program comprised mainly of base salary and equity, with a performance-based bonus provided to the Global Chief Executive Officer and Chief Accounting Officer, given the scope of their roles. The mix of these components depends on the executive officer’s role, performance, tenure and experience.

The Committee considered two types of potential base salary modifications for the named executive officers in 2024: (1) “merit increases” based upon each named executive’s individual performance; and/or (2) “market adjustments” based upon factors such as inflation, cost of living, and the salary ranges for similarly situated executives as compared to the peer group prepared by Compensia.

In determining merit increases, the Committee considered the specific responsibilities of the executive and the executive’s overall performance and tenure with the Company and feedback provided by the board of directors and other executives in the Company, with support from Human Resources.

The Committee determined any market adjustments based on market research conducted by Human Resources on factors such as inflation and cost of living, aligned with the direction for annual salary increases for non-executive employees, and the Committee’s comparison of the executive’s compensation with statistical information on average compensation for similarly situated executives in the peer group provided by Compensia. Each executive’s base salary was reviewed on its own, compared to the peer group, and in conjunction with the total compensation package (total cash and total compensation, including equity), compared to the peer group, in order to determine the appropriate mix. The Committee targeted below median for the entire compensation package (cash and equity together) for all of its executive officers compared to the peer group, given the Company’s smaller size relative to its peers. The Committee also considered the key market factors impacting the Company and its overall performance.

Pursuant to the terms of Mr. Holger Bartel’s employment agreement, dated September 28, 2015, as amended effective January 1, 2022, Mr. Bartel was eligible to receive an annual performance bonus for 2025 at the beginning of 2026, in an amount of up to $150,000 tied to three (3) strategic goals to be determined by the Compensation Committee at the beginning of each year. The amount of the bonus was reviewed by the Committee in the context of total cash compensation, relative to peers, and when combined with equity, relative to peers, to ensure below median targeting.

For 2025, the Committee determined that the goals would be: (1) a member target for Travelzoo North America and Europe; (2) an operating margin target (excluding certain member acquisition costs); and (3) a revenue growth target. Mr. Bartel achieved target (3) and substantially achieved target (1), thereby earning a pro-rated bonus of $95,750 paid in Q1 of 2026. Three new strategic goals were set by the Compensation Committee for 2026.

Ms. Lijun Qi has been on long-term disability leave since June 1, 2025 and therefore ineligible to receive performance bonuses since June 1, 2025.

Ms. Qi received discretionary bonuses totaling $25,000 for 2025.

None of the other named executive officers received a bonus opportunity in 2025.

As part of Mr. Holger Bartel’s compensation for 2024, the Compensation Committee granted Mr. Bartel stock options to purchase 600,000 shares of Common Stock with an exercise price of $8.58. The stock options vest bi-annually over two (2) years, beginning on June 30, 2024. The grant was subject to approval by the stockholders of the Company at the 2024 Annual Meeting and could have been unwound if approval was not received. However, the shareholders approved the grant. The options expire in 2029. No additional options were granted to Mr. Bartel in 2025. The Compensation Committee noted that (a) a significant portion of Mr. Holger Bartel’s compensation was stock-based compensation, (b) a significant portion of such stock-based compensation will expire in 2027, and (c) such stock-based compensation was underwater due to the performance of the Company’s common stock. In order to protect the Company from the loss of members of the executive team, the Compensation Committee and the Board approved a new grant for 2026, to be voted on as part of this proxy statement.

As part of Ms. Ciocca’s compensation for 2023, the Compensation Committee granted Ms. Ciocca stock options to purchase 200,000 shares of Common Stock with an exercise price of $4.96 per share. The stock options vest bi-annually over four (4) years, beginning on June 30, 2023. The grant was subject to approval by the stockholders of the Company at the 2023 Annual Meeting and could have been unwound if approval was not received. However, the shareholders approved the grant. The options expire in 2029. No additional options were granted to Ms. Ciocca in 2025.

None of the other named executive officers received an option grant in 2025.

Company Clawback Policy. Effective October 10, 2022, the Board approved the implementation of a clawback policy (the “Clawback Policy”), applicable to performance-based compensation (specifically, cash incentive/bonus awards and all forms of equity-based compensation) for Senior Executives in instances of fraud or willful misconduct that caused or otherwise contributed to the need for a material restatement of the Company’s financial results. “Senior Executives” is defined under the policy as the Company’s executive officers (as defined by the Securities and Exchange Act of 1934, as amended), other principal corporate officers (as elected by the Board) and other key employees who are designated from time to time by the Board. This Clawback Policy applied retrospectively to any outstanding option grants and prospectively to any new option grants. For more information, please review the Clawback Policy attached as Exhibit 97 to the Company’s Annual Report on Form 10-K, filed on March 19, 2025. This summary is qualified in its entirety by the Clawback Policy, which is incorporated by reference herein.

Perquisites and Additional Benefits. The Company seeks to maintain an open and inclusive culture in its facilities and operations among executives and other Company employees. Accordingly, the Company does not provide executives with reserved parking spaces or separate dining or other facilities, nor does the Company have programs for providing personal-benefit perquisites to executives, such as club dues or defraying the cost of personal entertainment. Named executive officers and employees may seek reimbursement for business related expenses in accordance with the Company’s business expense reimbursement policy.

Employment Agreements. The Company has entered into employment agreements with certain executive staff, some of which contain severance and change of control provisions. The terms of such employment agreements are described in more detail below in Employment Agreements and Potential Payments Upon Termination or Change-in-Control.

The following summary compensation table sets forth information concerning the compensation of our Global Chief Executive Officer, Chief Membership Officer and General Counsel, and Chief Accounting Officer during the fiscal years ended December 31, 2025 and 2024.

The following table sets forth certain information with respect to non-equity incentive plan awards granted to each of our named executive officers during the fiscal year ended December 31, 2025.

The following table sets forth certain information with respect to outstanding equity awards as of December 31, 2025.

In March 2023, the Company granted Ms. Ciocca 200,000 options, which vest semi-annually over 4 years, starting June 30, 2023. As of the end of 2025, 150,000 options vested and 50,000 remained unvested. In June 2025, Ms. Ciocca exercised 25,000 options via a cashless exercise approved by the Board of Directors, leaving 50,000 unexercised.

All 600,000 options pursuant to Mr. Bartel’s 2022 option grant vested by the end of 2023. In December 2024, Mr. Bartel exercised 200,000 options from the 2022 grant via a cashless exercise approved by the Board of Directors, leaving 400,000 unexercised.

All 600,000 options pursuant to Mr. Bartel’s 2024 option grant vested by the end of 2025. Mr. Bartel has not yet exercised any options pursuant to the 2024 grant.

The Company has employment agreements with its named executive officers. The employment agreements in place as of December 31, 2025 with the Company’s named executive officers are described below.

Mr. Holger Bartel entered into an employment agreement with the Company on September 28, 2015. The Company may terminate the employment agreement, with or without cause, upon written notice to Mr. Holger Bartel. However, if Mr. Holger Bartel’s employment is terminated at any time without cause, Mr. Holger Bartel’s remaining stock options will immediately vest in full on the date of termination. Mr. Holger Bartel agreed that the Company will own any discoveries and work product (as defined in the agreement) made during the term of his employment and to assign all of his interest in any and all such discoveries and work product to the Company. On October 1, 2023, Mr. Holger Bartel entered into a temporary secondment arrangement with Travelzoo (Europe) Limited to serve as its Head of Strategy in the United Kingdom, splitting time 30/70.

Ms. Ciocca entered into an employment agreement with the Company on April 2, 2018. Pursuant to the terms of the agreement, Ms. Ciocca is an at-will employee, meaning the Company or Ms. Ciocca could terminate the agreement at any time, with or without cause, upon two (2) weeks’ prior notice to the other party.

Ms. Ciocca agreed that the Company will own any discoveries and work product (as defined in the agreement) made during the term of her employment and to assign all of her interest in any and all such discoveries and work product to the Company. Furthermore, Ms. Ciocca agreed not to, directly or indirectly, solicit the Company’s customers or employees during the term of her employment and for a period of one (1) year thereafter.

Ms. Qi entered into an employment agreement with the Company on December 29, 2016. Pursuant to the terms of the agreement, Ms. Qi is an at-will employee, meaning the Company or Ms. Qi could terminate the agreement at any time, with or without cause, upon two (2) weeks’ prior notice to the other party.

Ms. Qi agreed that the Company will own any discoveries and work product (as defined in the agreement) made during the term of her employment and to assign all of her interest in any and all such discoveries and work product to the Company.

Compensation Actually Paid, as required under SEC rules, reflects adjusted values to unvested and vested equity awards during the years shown in the table based on year-end stock prices and various accounting valuation assumptions, but does not reflect actual amounts paid out for those awards. Compensation Actually Paid generally fluctuates due to stock price performance. We believe the “Compensation Actually Paid” in each of the years reported herein and over the three-year cumulative period are reflective of the Compensation Committee’s emphasis on “pay-for-performance” as the “Compensation Actually Paid” fluctuated year-over-year, primarily due to the result of our stock performance. Below are graphs showing the relationship of Compensation Actually Paid to our Global CEO and Non-PEO NEOs for 2023, 2024 and 2025 to (1) the Company’s cumulative TSR and (2) the Company’s net income:

Statements that do not relate strictly to historical or current facts are forward-looking and usually identified by the use of words such as “anticipate,” “estimate,” “approximate,” “expect,” “intend,” “plan,” “believe” and other words of similar meaning in connection with any discussion of future operating or financial matters. Without limiting the generality of the foregoing, forward-looking statements contained in this report include the matters discussed regarding the expectation of compensation plans, strategies, objectives, and growth and anticipated financial and operational performance of the Company and its subsidiaries. A variety of factors could cause the Company’s actual results to differ materially from the anticipated results or other expectations expressed in the Company’s forward-looking statements. The risks and uncertainties that may affect the operations, performance and results of the Company’s business and forward-looking statements include, but are not limited to, those set forth herein. Any forward-looking statement speaks only as of the date on which such statement is made and the Company does not intend to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise.

The following table shows the amount of our common stock beneficially owned as of March 5, 2026 by (a) each director and nominee for election to the Board of Directors, (b) each named executive officer, (c) all executive officers and directors as a group, and (d) each person known by the Company, as of March 5, 2026, to beneficially own more than 5% of the outstanding shares of Common Stock of the Company. In general, shares “beneficially owned” include those shares a person has (or shares) the power to vote, or the power to dispose of.

Under Section 16(a) of the Securities Exchange Act of 1934, the Company’s directors, executive officers and the beneficial holders of more than 10% of the Company’s Common Stock are required to file reports of ownership and changes in ownership with the SEC. Such directors, executive officers and beneficial holders of more than 10% of the Company’s Common Stock are required by SEC regulations to furnish the Company with copies of all Section 16(a) forms they file.

To the Company’s knowledge, based solely on a review of the copies of such forms furnished to the Company or written representations from reporting persons, during fiscal year 2025, all Section 16(a) filing requirements were satisfied on a timely basis, except for one Form 4 filing relating to a single transaction that was filed late due to administrative error on December 8, 2025 on behalf of Azzurro Capital Inc.

KPMG LLP (“KPMG”) served as Travelzoo’s independent registered public accounting firm for our 2025 and 2024 fiscal years.

The Audit Committee annually reviews the performance of our independent registered public accounting firm and the fees charged for their services. This review has been completed for 2025. Based upon the results of this review, the Audit Committee determined to engage KPMG again as the Company’s independent registered public accounting firm and to perform our annual audit for the fiscal year ended 2026. Stockholder approval of our accounting firm is not required by our Amended and Restated By-laws or otherwise required to be submitted to the stockholders. KPMG representatives are expected to be present at the Annual Meeting and will be available to respond to questions at the meeting; however, they are not expected to make a formal statement.

The audit fees and fees for services rendered to Travelzoo charged by KPMG for 2025 and 2024 are as follows:

The Audit Committee pre-approves all audit and permissible non-audit services provided by the Company’s independent registered public accounting firm. These services may include audit services, audit related services, tax and other services. Pre-approval is generally provided for up to one year, and any pre-approval is detailed as to the particular service or category of services and is generally subject to a specific budget. The independent registered public accounting firm and management are required to periodically report to the Audit Committee regarding the extent of services provided by the independent registered public accounting firm in accordance with this pre-approval, and the fees for the services performed to date. The Audit Committee may also pre-approve particular services on a case-by-case basis. During 2025 and 2024, all services provided by KPMG were pre-approved by the Audit Committee in accordance with this policy.

The information contained in this report shall not be deemed to be “soliciting material” or “filed” with the SEC or subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), except to the extent that Travelzoo specifically incorporates it by reference into a document filed under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act.

The Audit Committee oversees Travelzoo’s financial reporting process on behalf of the Board of Directors. Management is primarily responsible for the financial statements and reporting processes including the systems of internal controls, while the independent auditors are responsible for performing an independent audit of Travelzoo’s consolidated financial statements in accordance with auditing standards of the Public Company Accounting Oversight Board (“PCAOB”), and expressing an opinion on the conformity of those financial statements with accounting principles generally accepted in the United States.

In this context, the committee has met and held discussions with management and the independent auditors regarding the Company’s audited consolidated financial statements for the fiscal year ended December 31, 2025. The committee discussed with Travelzoo’s independent auditors the overall scope and plan for their audit. The committee met, at least quarterly, with the independent auditors, with and without management present, and discussed the results of their examinations, their evaluations of Travelzoo’s internal controls, and the overall quality of Travelzoo’s financial reporting. Management represented to the committee that Travelzoo’s consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States. The committee has reviewed and discussed the consolidated financial statements with management and the independent auditors, including their judgments as to the quality, not just the acceptability, of Travelzoo’s accounting principles and such other matters as are required to be discussed with the committee under auditing standards of the PCAOB.

Travelzoo’s independent auditors also provided to the committee the written disclosures required by applicable requirements of the PCAOB regarding the independent accountant’s communications with the Audit Committee concerning independence, and the committee discussed with the independent auditors that firm’s independence, including those matters required to be discussed by PCAOB Auditing Standard No. 16 Communications with Audit Committees.

In reliance on the reviews and discussions referred to above, the committee recommended to the Board of Directors (and the Board of Directors has approved) that the audited financial statements be included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 11, 2026.

While the committee has the responsibilities and powers set forth in its charter, it is not the duty of the committee to plan or conduct audits or to determine that Travelzoo’s financial statements are complete and accurate and are in accordance with generally accepted accounting principles. This is the responsibility of management and the independent auditors. Nor is it the duty of the committee to conduct investigations or to ensure compliance with laws and regulations or Travelzoo’s business conduct policies.

The SEC allows us to “incorporate by reference” information into this document. This means that the Company can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be a part of this document, except for any information that is superseded by information that is included directly in this document or in any other subsequently filed document that also is incorporated by reference herein.

This document incorporates by reference our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC and contains important information about the Company and its financial condition, including information contained in our 2025 Annual Report under the captions “Financial Statements and Supplementary Data,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Changes in and Disagreements with Accountants on Accounting and Financial Disclosure,” and “Quantitative and Qualitative Disclosures about Market Risk.” A copy of the 2025 Annual Report accompanies this proxy statement.

The Company will amend this proxy statement to include or incorporate by reference any additional documents that the Company may file with the Securities and Exchange Commission under Section 13(a), 13(e), 14, or 15(d) of the Exchange Act after the date of this document to the extent required to fulfill our disclosure obligations under the Exchange Act.

The Company will provide, without charge, to each person to whom this proxy statement is delivered, upon written or oral request of such person and by first class mail or other equally prompt means within one business day of receipt of such request, a copy of any and all information that has been incorporated by reference in this proxy statement. You may obtain a copy of these documents and any amendments thereto by contacting Investor Relations, Travelzoo, 590 Madison Avenue, 35th Floor, New York, New York 10022 or by telephone at (212) 516-1300. This proxy statement and the 2025 Annual Report are available on the Internet at http://ir.travelzoo.com/financials-filings/annual-reports-and-proxies. These documents are also included in our SEC filings, which you can access electronically at the SEC’s website at http://www.sec.gov.

We are subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended, and in accordance therewith, we file periodic reports, documents and other information with the SEC relating to our business, financial statements and other matters. Such reports and other information may be inspected and are available for copying at the offices of the SEC, 100 F Street, N.E., Washington, D.C. 20549 or may be accessed at www.sec.gov. Information regarding the operation of the public reference rooms may be obtained by calling the SEC at 1-800-SEC-0330. You are encouraged to review the annual report on Form 10-K, as amended, mailed along with these proxy materials, together with any subsequent information we filed or will file with the SEC and other publicly available information. A copy of any public filing is also available, at no charge, by contacting Investor Relations, Travelzoo, 590 Madison Avenue, 35th Floor, New York, New York 10022 or by telephone at (212) 516-1300.

No director, executive officer, nominee for election as a director or associate of any director, executive officer or nominee has any substantial interest, direct or indirect, by security holdings or otherwise, in the proposed matters to be acted upon, other than director elections and executive compensation, which is not shared by all other stockholders.

The Board does not presently intend to bring any other business before the meeting and, so far as is known to the Board, no matters are to be brought before the meeting except as specified in the Notice of Annual Meeting of Stockholders. As to any business that may properly come before the meeting, however, it is intended that proxies, in the form enclosed, will be voted in respect thereof in accordance with the judgment of the persons voting such proxies.

It is contemplated that the next annual meeting of stockholders will be held on or about April 21, 2027. Stockholders may submit proposals on matters appropriate for stockholder action at annual meetings in accordance with the Company’s Amended and Restated By-laws and the rules and regulations adopted by the SEC. For a stockholder proposal to be included in the Company’s proxy statement and identified in its form of proxy in connection with the Company’s annual meeting of stockholders, it must be received by the Company at least 120 calendar days prior to the one-year anniversary of the date that the Company’s proxy statement was released to the stockholders in connection with the previous year’s annual meeting. As a result, stockholder proposals submitted for consideration at the 2027 annual meeting must be received no later than November 11, 2026, to be included in the 2027 proxy materials. Rule 14a-8 of the Exchange Act provides additional information regarding the content and the procedures applicable to the submission of stockholder proposals to be included in the Company’s proxy materials for its next Annual Meeting.

Any such notice must be delivered or mailed to our Corporate Secretary, at Travelzoo, 590 Madison Avenue, 35^th Floor, New York, NY 10022.

We have adopted a procedure approved by the SEC called “householding.” Under this procedure, a householding notice will be sent to stockholders who have the same address and last name and do not participate in electronic delivery of proxy materials, and they will receive only one copy of our annual report and proxy statement unless one or more of these stockholders notifies us that they wish to not participate in householding and continue receiving individual copies. This procedure reduces our printing costs and postage fees. Each stockholder who participates in householding will continue to receive a separate proxy card.

The Company will promptly deliver, upon oral or written request, a separate copy of the proxy statement and annual report to any stockholder participating in householding. Stockholders who share an address with other stockholders and are eligible for householding, but currently receive multiple copies of our annual reports and proxy statements, or who have multiple accounts in their names, can authorize us to discontinue mailings of multiple annual reports and proxy statements. Requests for additional copies, or requests for a single copy to be delivered to a shared address should be directed to Investor Relations, Travelzoo, 590 Madison Avenue, 35th Floor, New York, New York 10022 or by telephone at +1 (212) 516-1300.

THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) is made this day of February 19, 2026, by and between Travelzoo, a Delaware corporation (the “Company”) and Holger Bartel (“Optionee”).

WHEREAS, Optionee has been providing services for the Company pursuant to an Employment Agreement, dated as of September 28, 2015, as amended, by and between Optionee and the Company (“Employment Agreement”); and

WHEREAS, the Company desires to grant to Optionee the option to purchase certain shares of its stock, in accordance with the terms of this Agreement, with such option intended to be a non-statutory stock option that is not an incentive stock option within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended.

NOW, THEREFORE, in consideration of the premises and of the mutual agreements hereinafter set forth, it is covenanted and agreed as follows:

1. Grant and Terms of Option. Pursuant to action of the Compensation Committee (the “Committee”) of the Board of Directors of the Company (the “Board”), the Company grants, effective February 19, 2026 (“Date of Grant”) to Optionee the option to purchase all or any part of Six Hundred Thousand (600,000) shares of the common stock of the Company, par value of $0.01 each (“Common Stock”), to vest bi-annually over a period of two (2) years as set forth in the table below, at the purchase price of $5.05 per share, which is the fair market value of the Common Stock determined as the official NASDAQ closing share price on the Date of Grant; provided, however, that the right to exercise such option shall be, and is hereby, restricted as follows:

(a) No shares may be purchased until they have vested in accordance with the terms of this Agreement. Subject to the terms of this Agreement, the 600,000 stock options shall vest in four (4) bi-annual installments as follows:

On or after December 31, 2027, during the term hereof, Optionee will become entitled to purchase the entire number of shares (600,000 shares) to which this option relates.

(b) In no event may this option or any part thereof be exercised after the expiration of five (5) years from the Date of Grant, which shall be the term of the option.

(c) The purchase price of the shares subject to the option may be paid for (i) in cash, (ii) in the discretion of the Board, by tender of shares of Common Stock already owned by Optionee, or (iii) in the discretion of the Board, by such other method as the Board may determine.

(d) The option may not be exercised for a fraction of a share.

(e) The option may not be exercised if Optionee is no longer employed by the Company subject to the provisions of Section 4 of this Agreement.

(f) The option may not be exercised (i) unless and until stockholder approval is obtained and (ii) prior to the registration of the shares being offered under this Agreement, which registration shall be filed by the Company with the United States Securities and Exchange Commission following the Company’s next annual shareholder meeting. If stockholder approval for the option is not obtained, this grant shall be unwound and the outstanding options cancelled.

(g) The Board or the Committee shall also determine the methods by which shares of stock shall be delivered or deemed to be delivered to Optionee.

(h) The exercise price as set forth in Section 1 hereof shall not be modified and the number of shares granted pursuant to this Agreement as set forth in Section 1 hereof shall not be adjusted upwards, in each case, unless approved by a majority of unaffiliated stockholders.

2. Anti-Dilution Provisions. In the event that, during the term of this Agreement, there is any change in the number of shares of outstanding Common Stock of the Company by reason of stock dividends, recapitalizations, mergers, consolidations, split-ups, combinations or exchanges of shares and the like, not including any issuances of shares for consideration or capital increases by the Company, the number of shares covered by this Agreement and the price thereof shall be adjusted, to the same proportionate number of shares and price as in this Agreement.

3. Transferability. Neither the option hereby granted nor any rights thereunder or under this Agreement may be assigned, transferred or in any manner encumbered except to family members and/or entities owned or controlled by family members, and by will or the laws of descent and distribution, and any attempted assignment, transfer, mortgage, pledge or encumbrance except as herein authorized, shall be void and of no effect. For the avoidance of doubt, “family members” includes spouse, parents, children, siblings, mothers and fathers-in-law, sons and daughters-in-law, brothers and sisters-in-law. Additionally, “family members” also includes anyone (other than domestic employees) who share such person’s home.

The option may be exercised during Optionee’s lifetime only by Optionee or his transferee, guardian or legal representative as set forth herein.

4. Termination of Employment. In the event of the termination of the Employment Agreement prior to its expiration, or to the extent the Company terminates employment of Optionee, including upon death or disability, Optionee’s (or, in the event of death, the legatee or legatees of Optionee under his last will, or his personal representatives or distributees, or in the event of a transfer in accordance with Section 3, his transferee) right to exercise the option, only to the extent it was vested and he was entitled to exercise it on the date of termination of services or employment, shall continue for 90 days after such termination but not after five (5) years from the Date of Grant. If Optionee (or, in the event of death, the legatee or legatees of Optionee under his last will, or his personal representatives or distributees, or in the event of a transfer in accordance with Section 3, his transferee) does not exercise the option within 90 days following such termination of employment, any unexercised vested option shall be null and void. For the avoidance of doubt, an amendment of the Employment Agreement or employment relationship shall not constitute a termination of the Employment Agreement or employment of Optionee for purposes of this Section 4.

5. Method of Exercise/Shares Issued on Exercise of Option. The option may be exercised (in whole or in part) at any time during the period specified in this Agreement, (a) by delivering to the Corporate Secretary of the Company not less than thirty (30) days prior to the date of exercise (or such shorter period as the Company shall approve) a written notice (email being acceptable) of Optionee’s intent to exercise and estimated date of exercise, and (b) by delivering to the Corporate Secretary of the Company not less than five (5) business days prior to the date of exercise (or such shorter period as the Company shall approve) (i) a written notice of exercise designating the number of shares to be purchased, signed by Optionee, and (ii) payment of the full amount of the purchase price of the shares and payment of the full amount of applicable taxes triggered by the exercise of the shares, in each case, with respect to which the option is exercised. If the written notice of exercise is delivered by mail, or by any other means of delivery, the date of delivery shall be the date the written notice is actually received by the Corporate Secretary. It is the intention of the Company that on any exercise of this option it will transfer to Optionee shares of its authorized but unissued stock or transfer Treasury shares or utilize any combination of Treasury shares and authorized but unissued shares, to satisfy its obligations to deliver shares on any exercise hereof. No rights of a shareholder shall exist with respect to the Common Stock under this option as a result of the mere grant of this option.

6. Board Administration. The Board, the Committee, or any successor or other committee authorized by the Board, subject to the express terms of this option, shall have plenary authority to interpret any provision of this option and to make any determinations necessary or advisable for the administration of this option and the exercise of the rights herein granted, and may waive or amend any provisions hereof in any manner not adversely affecting the rights granted to Optionee by the express terms hereof.

7. Option not an Incentive Stock Option. It is intended that this option shall not be treated as an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended, or otherwise qualify for any special tax benefits to Optionee.

8. No Contract of Employment. Nothing contained in this Agreement shall be considered or construed as creating a contract of employment for any specified period of time.

9. Restrictions on Exercise. This option may not be exercised if the issuance of Common Stock upon Optionee’s exercise or the method of payment of consideration for such Common Stock would constitute a violation of any applicable Federal or state securities law or other applicable law or regulation. As a condition to the exercise of this option, the Company may require Optionee to make any representations and warranty to the Company as may be required by any applicable law or regulation.

10. Termination of Option. Notwithstanding anything to the contrary herein, this option shall not be exercisable after the expiration of the term of five (5) years from the Date of Grant, as set forth in section 1(b) hereof.

11. Withholding upon Exercise. Prior to the issuance of shares upon the exercise of the option, the Optionee must make arrangements satisfactory to the Company to pay or provide for any applicable federal, state and local withholding obligations of the Company. The Optionee may satisfy any federal, state or local tax withholding obligation relating to the exercise of the option by any of the following means: (a) tendering a cash payment; or (b) requesting that the Company (which may or may not approve in its sole discretion) withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Optionee as a result of the exercise of the option; provided, however, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax required to be withheld by law. The Company reserves the right to withhold, in accordance with any applicable laws, from any consideration payable to Optionee any taxes required to be withheld by federal, state or local law as a result of the grant or exercise of this option. If the amount of any consideration payable to Optionee is insufficient to pay such taxes or if no consideration is payable to Optionee, upon request of the Company, Optionee shall pay to the Company in cash an amount sufficient for the Company to satisfy any Federal, state or local tax withholding requirements it may incur as a result of the grant or exercise of this option. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding (”Tax-Related Items”), the ultimate liability for all Tax-Related Items is and remains the Optionee’s responsibility and the Company (a) makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with the grant, vesting, or exercise of the option or the subsequent sale of any shares acquired on exercise; and (b) does not commit to structure the option to reduce or eliminate the Optionee’s liability for Tax-Related Items.

12. Clawback Policy. Notwithstanding any other provision of this Agreement to the contrary, any cash incentive compensation received by Optionee and/or shares of Common Stock issued hereunder, and/or any amount received with respect to any sale of any such shares of Common Stock, shall be subject to potential cancellation, recoupment, rescission, payback or other action in accordance with the terms of the Company’s Clawback Policy, as it may be amended from time to time (the “Policy”). Optionee agrees and consents to the Company’s application, implementation and enforcement of (a) the Policy or any similar policy established by the Company that may apply to Optionee and (b) any provision of applicable law relating to cancellation, rescission, payback or recoupment of compensation, and expressly agrees that the Company may take such actions as are necessary to effectuate the Policy, any similar policy (as applicable to Optionee) or applicable law without further consent or action being required by Optionee. To the extent that the terms of this Agreement and the Policy or any similar policy conflict, then the terms of such policy shall prevail.

13. Severability. Any word, phrase, clause, sentence or other provision herein which violates or is prohibited by any applicable law, court decree or public policy shall be modified as necessary to avoid the violation or prohibition and so as to make this Agreement enforceable as fully as possible under applicable law, and if such cannot be so modified, the same shall be ineffective to the extent of such violation or prohibition without invalidating or affecting the remaining provisions herein.

14. Non-Waiver of Rights. The Company’s failure to enforce at any time any of the provisions of this Agreement or to require at any time performance by Optionee of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect either the validity of this Agreement, or any part hereof, or the right of the Company thereafter to enforce each and every provision in accordance with the terms of this Agreement.

15. Entire Agreement; Amendments. No modification, amendment or waiver of any of the provisions of this Agreement shall be effective unless in writing specifically referring hereto and signed by the parties hereto. This Agreement supersedes all prior agreements and understandings between Optionee and the Company to the extent that any such agreements or understandings conflict with the terms of this Agreement.

16. Assignment. This Agreement shall be freely assignable by the Company and shall inure to the benefit of, and be binding upon, the Company, its successors and assigns and/or any other entity which shall succeed to the business presently being conducted by the Company.

17. Governing Law. To the extent that Federal laws do not otherwise control, all determinations made, or actions taken pursuant hereto shall be governed by the laws of the State of New York, without regard to the conflict of laws rules thereof.

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed on its behalf by the undersigned officer pursuant to due authorization, and Optionee has signed this Agreement to evidence his acceptance of the option herein granted and of the terms hereof, all as of the date hereof.

THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) is made this day of December 30, 2025, by and between Travelzoo, a Delaware corporation (the “Company”) and Jason Bushman (“Optionee”).

WHEREAS, the Optionee has been providing services to the Company, pursuant to an Amended and Restated Employment Agreement, dated as of February 11, 2025 (the “Employment Agreement”); and

WHEREAS, the Company desires to grant to Optionee the option to purchase certain shares of its stock, in accordance with the terms of this Agreement, with such option intended to be a non-statutory stock option that is not an incentive stock option within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended.

NOW, THEREFORE, in consideration of the premises and of the mutual agreements hereinafter set forth, it is covenanted and agreed as follows:

1. Grant and Terms of Option. Pursuant to action of the Compensation Committee (the “Committee”) of the Board of Directors of the Company (the “Board”), the Company grants, effective December 29, 2025 (“Date of Grant”) to Optionee the option to purchase all or any part of fifty thousand (50,000) shares of the common stock of the Company, par value of $0.01 each (“Common Stock”), to vest annually over a period of four (4) years as set forth in the table below, at the purchase price of $7.14 per share, which is the fair market value of the Common Stock determined as the official Nasdaq closing share price on the Date of Grant; provided, however, that the right to exercise such option shall be, and is hereby, restricted as follows:

(a) No shares may be purchased until they have vested in accordance with the terms of this Agreement. Subject to the terms of this Agreement, the 50,000 stock options shall vest in four (4) annual installments as follows:

On or after September 1, 2029, during the term hereof, Optionee will become entitled to purchase the entire number of shares (50,000 shares) to which this option relates.

(b) In no event may this option or any part thereof be exercised after the expiration of five (5) years from the Date of Grant, which shall be the term of the option.

(c) The purchase price of the shares subject to the option may be paid for (i) in cash, (ii) in the discretion of the Board, by tender of shares of Common Stock already owned by Optionee, or (iii) in the discretion of the Board, by such other method as the Board may determine.

(d) The option may not be exercised for a fraction of a share.

(e) The option may not be exercised if Optionee is no longer employed by the Company subject to the provisions of Section 4 of this Agreement.

(f) The option may not be exercised (i) unless and until stockholder approval is obtained and (ii) prior to the registration of the shares being offered under this Agreement, which registration shall be filed by the Company with the United States Securities and Exchange Commission following the Company’s next annual shareholder meeting. If stockholder approval for the option is not obtained, this grant shall be unwound and the outstanding options cancelled.

(g) The Board or the Committee shall also determine the methods by which shares of stock shall be delivered or deemed to be delivered to Optionee.

2. Anti-Dilution Provisions. In the event that, during the term of this Agreement, there is any change in the number of shares of outstanding Common Stock of the Company by reason of stock dividends, recapitalizations, mergers, consolidations, split-ups, combinations or exchanges of shares and the like, not

including any issuances of shares for consideration or capital increases by the Company, the number of shares covered by this Agreement and the price thereof shall be adjusted, to the same proportionate number of shares and price as in this Agreement.

3. Non-Transferability. Neither the option hereby granted nor any rights thereunder or under this Agreement may be assigned, transferred or in any manner encumbered except by will or the laws of descent and distribution, and any attempted assignment, transfer, mortgage, pledge or encumbrance except as herein authorized, shall be void and of no effect.

The option may be exercised during Optionee’s lifetime only by Optionee or his guardian or legal representative as set forth herein.

4. Termination of Employment. In the event of the termination of the Employment Agreement prior to its expiration, or to the extent the Company terminates employment of Optionee, including upon death or disability, Optionee’s (or, in the event of death, the legatee or legatees of Optionee under his last will, or his personal representatives or distributees) right to exercise the option, only to the extent it was vested and he was entitled to exercise it on the date of termination of services or employment, shall continue for 90 days after such termination but not after five (5) years from the Date of Grant. If Optionee (or, in the event of death, the legatee or legatees of Optionee under his last will, or his personal representatives or distributees) does not exercise the option within 90 days following such termination of employment, any unexercised vested option shall be null and void.

5. Method of Exercise/Shares Issued on Exercise of Option. The option may be exercised (in whole or in part) at any time during the period specified in this Agreement, (a) by delivering to the Corporate Secretary of the Company not less than thirty (30) days prior to the date of exercise (or such shorter period as the Company shall approve) a written notice (email being acceptable) of Optionee’s intent to exercise and estimated date of exercise, and (b) by delivering to the Corporate Secretary of the Company not less than five (5) business days prior to the date of exercise (or such shorter period as the Company shall approve) (i) a written notice of exercise designating the number of shares to be purchased, signed by Optionee, and (ii) payment of the full amount of the purchase price of the shares and payment of the full amount of applicable taxes triggered by the exercise of the shares, in each case, with respect to which the option is exercised. If the written notice of exercise is delivered by mail, or by any other means of delivery, the date of delivery shall be the date the written notice is actually received by the Corporate Secretary. It is the intention of the Company that on any exercise of this option it will transfer to Optionee shares of its authorized but unissued stock or transfer Treasury shares or utilize any combination of Treasury shares and authorized but unissued shares, to satisfy its obligations to deliver shares on any exercise hereof. No rights of a shareholder shall exist with respect to the Common Stock under this option as a result of the mere grant of this option.

6. Board Administration. The Board, the Committee, or any successor or other committee authorized by the Board, subject to the express terms of this option, shall have plenary authority to interpret any provision of this option and to make any determinations necessary or advisable for the administration of this option and the exercise of the rights herein granted, and may waive or amend any provisions hereof in any manner not adversely affecting the rights granted to Optionee by the express terms hereof.

7. Option not an Incentive Stock Option. It is intended that this option shall not be treated as an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended, or otherwise qualify for any special tax benefits to Optionee.

8. No Contract of Employment. Nothing contained in this Agreement shall be considered or construed as creating a contract of employment for any specified period of time.

9. Restrictions on Exercise. This option may not be exercised if the issuance of Common Stock upon Optionee’s exercise or the method of payment of consideration for such Common Stock would constitute a violation of any applicable Federal or state securities law or other applicable law or regulation. As a condition to the exercise of this option, the Company may require Optionee to make any representations and warranty to the Company as may be required by any applicable law or regulation.

10. Termination of Option. Notwithstanding anything to the contrary herein, this option shall not be exercisable after the expiration of the term of five (5) years from the Date of Grant, as set forth in section 1(b) hereof.

11. Withholding upon Exercise. Prior to the issuance of shares upon the exercise of the option, the Optionee must make arrangements satisfactory to the Company to pay or provide for any applicable federal, state and local withholding obligations of the Company. The Optionee may satisfy any federal, state or local tax withholding obligation relating to the exercise of the option by any of the following means: (a) tendering a cash payment; or (b) requesting that the Company (which may or may not approve in its sole discretion) withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Optionee as a result of the exercise of the option; provided, however, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax required to be withheld by law. The Company reserves the right to withhold, in accordance with any applicable laws, from any consideration payable to Optionee any taxes required to be withheld by federal, state or local law as a result of the grant or exercise of this option. If the amount of any consideration payable to Optionee is insufficient to pay such taxes or if no consideration is payable to Optionee, upon request of the Company, Optionee shall pay to the Company in cash an amount sufficient for the Company to satisfy any Federal, state or local tax withholding requirements it may incur as a result of the grant or exercise of this option. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding (”Tax-Related Items”), the ultimate liability for all Tax-Related Items is and remains the Optionee’s responsibility and the Company (a) makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with the grant, vesting, or exercise of the option or the subsequent sale of any shares acquired on exercise; and (b) does not commit to structure the option to reduce or eliminate the Optionee’s liability for Tax-Related Items.

12. Clawback Policy. Notwithstanding any other provision of this Agreement to the contrary, any cash incentive compensation received by Optionee and/or shares of Common Stock issued hereunder, and/or any amount received with respect to any sale of any such shares of Common Stock, shall be subject to potential cancellation, recoupment, rescission, payback or other action in accordance with the terms of the Company’s Clawback Policy, as it may be amended from time to time (the “Policy”). Optionee agrees and consents to the Company’s application, implementation and enforcement of (a) the Policy or any similar policy established by the Company that may apply to Optionee and (b) any provision of applicable law relating to cancellation, rescission, payback or recoupment of compensation, and expressly agrees that the Company may take such actions as are necessary to effectuate the Policy, any similar policy (as applicable to Optionee) or applicable law without further consent or action being required by Optionee. To the extent that the terms of this Agreement and the Policy or any similar policy conflict, then the terms of such policy shall prevail.

13. Severability. Any word, phrase, clause, sentence or other provision herein which violates or is prohibited by any applicable law, court decree or public policy shall be modified as necessary to avoid the violation or prohibition and so as to make this Agreement enforceable as fully as possible under applicable law, and if such cannot be so modified, the same shall be ineffective to the extent of such violation or prohibition without invalidating or affecting the remaining provisions herein.

14. Non-Waiver of Rights. The Company’s failure to enforce at any time any of the provisions of this Agreement or to require at any time performance by Optionee of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect either the validity of this Agreement, or any part hereof, or the right of the Company thereafter to enforce each and every provision in accordance with the terms of this Agreement.

15. Entire Agreement; Amendments. No modification, amendment or waiver of any of the provisions of this Agreement shall be effective unless in writing specifically referring hereto and signed by the parties hereto. This Agreement supersedes all prior agreements and understandings between Optionee and the Company to the extent that any such agreements or understandings conflict with the terms of this Agreement.

16. Assignment. This Agreement shall be freely assignable by the Company and shall inure to the benefit of, and be binding upon, the Company, its successors and assigns and/or any other entity which shall succeed to the business presently being conducted by the Company.

17. Governing Law. To the extent that Federal laws do not otherwise control, all determinations made, or actions taken pursuant hereto shall be governed by the laws of the State of New York, without regard to the conflict of laws rules thereof.

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed on its behalf by the undersigned officer pursuant to due authorization, and Optionee has signed this Agreement to evidence his acceptance of the option herein granted and of the terms hereof, all as of the date hereof.

THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) is made this day of March 4, 2026, by and between Travelzoo, a Delaware corporation (the “Company”) and Azar Hashemi (“Optionee”).

WHEREAS, the Optionee has been providing services to the Company pursuant to an Amended and Restated Employment Agreement, dated as of June 1, 2021 (the “Employment Agreement”); and

WHEREAS, the Company desires to grant to Optionee the option to purchase certain shares of its stock, in accordance with the terms of this Agreement, with such option intended to be a non-statutory stock option that is not an incentive stock option within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended.

NOW, THEREFORE, in consideration of the premises and of the mutual agreements hereinafter set forth, it is covenanted and agreed as follows:

1. Grant and Terms of Option. Pursuant to action of the Compensation Committee (the “Committee”) of the Board of Directors of the Company (the “Board”), the Company grants, effective March 4, 2026 (“Date of Grant”) to Optionee the option to purchase all or any part of fifty thousand (50,000) shares of the common stock of the Company, par value of $0.01 each (“Common Stock”), to vest annually over a period of four (4) years as set forth in the table below, at the purchase price of $6.28 per share, which is the fair market value of the Common Stock determined as the official Nasdaq closing share price on the Date of Grant; provided, however, that the right to exercise such option shall be, and is hereby, restricted as follows:

(a) No shares may be purchased until they have vested in accordance with the terms of this Agreement. Subject to the terms of this Agreement, the 50,000 stock options shall vest in four (4) annual installments as follows:

On or after March 4, 2030, during the term hereof, Optionee will become entitled to purchase the entire number of shares (50,000 shares) to which this option relates.

(b) In no event may this option or any part thereof be exercised after the expiration of five (5) years from the Date of Grant, which shall be the term of the option.

(c) The purchase price of the shares subject to the option may be paid for (i) in cash, (ii) in the discretion of the Board, by tender of shares of Common Stock already owned by Optionee, or (iii) in the discretion of the Board, by such other method as the Board may determine.

(d) The option may not be exercised for a fraction of a share.

(e) The option may not be exercised if Optionee is no longer employed by the Company subject to the provisions of Section 4 of this Agreement.

(f) The option may not be exercised (i) unless and until stockholder approval is obtained and (ii) prior to the registration of the shares being offered under this Agreement, which registration shall be filed by the Company with the United States Securities and Exchange Commission following the Company’s next annual shareholder meeting. If stockholder approval for the option is not obtained, this grant shall be unwound and the outstanding options cancelled.

(g) The Board or the Committee shall also determine the methods by which shares of stock shall be delivered or deemed to be delivered to Optionee.

2. Anti-Dilution Provisions. In the event that, during the term of this Agreement, there is any change in the number of shares of outstanding Common Stock of the Company by reason of stock dividends,

recapitalizations, mergers, consolidations, split-ups, combinations or exchanges of shares and the like, not including any issuances of shares for consideration or capital increases by the Company, the number of shares covered by this Agreement and the price thereof shall be adjusted, to the same proportionate number of shares and price as in this Agreement.

3. Non-Transferability. Neither the option hereby granted nor any rights thereunder or under this Agreement may be assigned, transferred or in any manner encumbered except by will or the laws of descent and distribution, and any attempted assignment, transfer, mortgage, pledge or encumbrance except as herein authorized, shall be void and of no effect.

The option may be exercised during Optionee’s lifetime only by Optionee or his guardian or legal representative as set forth herein.

4. Termination of Employment. In the event of the termination of the Employment Agreement prior to its expiration, or to the extent the Company terminates employment of Optionee, including upon death or disability, Optionee’s (or, in the event of death, the legatee or legatees of Optionee under his last will, or his personal representatives or distributees) right to exercise the option, only to the extent it was vested and he was entitled to exercise it on the date of termination of services or employment, shall continue for 90 days after such termination but not after five (5) years from the Date of Grant. If Optionee (or, in the event of death, the legatee or legatees of Optionee under his last will, or his personal representatives or distributees) does not exercise the option within 90 days following such termination of employment, any unexercised vested option shall be null and void.

5. Method of Exercise/Shares Issued on Exercise of Option. The option may be exercised (in whole or in part) at any time during the period specified in this Agreement, (a) by delivering to the Corporate Secretary of the Company not less than thirty (30) days prior to the date of exercise (or such shorter period as the Company shall approve) a written notice (email being acceptable) of Optionee’s intent to exercise and estimated date of exercise, and (b) by delivering to the Corporate Secretary of the Company not less than five (5) business days prior to the date of exercise (or such shorter period as the Company shall approve) (i) a written notice of exercise designating the number of shares to be purchased, signed by Optionee, and (ii) payment of the full amount of the purchase price of the shares and payment of the full amount of applicable taxes triggered by the exercise of the shares, in each case, with respect to which the option is exercised. If the written notice of exercise is delivered by mail, or by any other means of delivery, the date of delivery shall be the date the written notice is actually received by the Corporate Secretary. It is the intention of the Company that on any exercise of this option it will transfer to Optionee shares of its authorized but unissued stock or transfer Treasury shares or utilize any combination of Treasury shares and authorized but unissued shares, to satisfy its obligations to deliver shares on any exercise hereof. No rights of a shareholder shall exist with respect to the Common Stock under this option as a result of the mere grant of this option.

6. Board Administration. The Board, the Committee, or any successor or other committee authorized by the Board, subject to the express terms of this option, shall have plenary authority to interpret any provision of this option and to make any determinations necessary or advisable for the administration of this option and the exercise of the rights herein granted, and may waive or amend any provisions hereof in any manner not adversely affecting the rights granted to Optionee by the express terms hereof.

7. Option not an Incentive Stock Option. It is intended that this option shall not be treated as an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended, or otherwise qualify for any special tax benefits to Optionee.

8. No Contract of Employment. Nothing contained in this Agreement shall be considered or construed as creating a contract of employment for any specified period of time.

9. Restrictions on Exercise. This option may not be exercised if the issuance of Common Stock upon Optionee’s exercise or the method of payment of consideration for such Common Stock would constitute a violation of any applicable Federal or state securities law or other applicable law or regulation. As a condition to the exercise of this option, the Company may require Optionee to make any representations and warranty to the Company as may be required by any applicable law or regulation.

10. Termination of Option. Notwithstanding anything to the contrary herein, this option shall not be exercisable after the expiration of the term of five (5) years from the Date of Grant, as set forth in section 1(b) hereof.

11. Withholding upon Exercise. Prior to the issuance of shares upon the exercise of the option, the Optionee must make arrangements satisfactory to the Company to pay or provide for any applicable federal, state and local withholding obligations of the Company. The Optionee may satisfy any federal, state or local tax withholding obligation relating to the exercise of the option by any of the following means: (a) tendering a cash payment; or (b) requesting that the Company (which may or may not approve in its sole discretion) withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Optionee as a result of the exercise of the option; provided, however, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax required to be withheld by law. The Company reserves the right to withhold, in accordance with any applicable laws, from any consideration payable to Optionee any taxes required to be withheld by federal, state or local law as a result of the grant or exercise of this option. If the amount of any consideration payable to Optionee is insufficient to pay such taxes or if no consideration is payable to Optionee, upon request of the Company, Optionee shall pay to the Company in cash an amount sufficient for the Company to satisfy any Federal, state or local tax withholding requirements it may incur as a result of the grant or exercise of this option. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding (”Tax-Related Items”), the ultimate liability for all Tax-Related Items is and remains the Optionee’s responsibility and the Company (a) makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with the grant, vesting, or exercise of the option or the subsequent sale of any shares acquired on exercise; and (b) does not commit to structure the option to reduce or eliminate the Optionee’s liability for Tax-Related Items.

12. Clawback Policy. Notwithstanding any other provision of this Agreement to the contrary, any cash incentive compensation received by Optionee and/or shares of Common Stock issued hereunder, and/or any amount received with respect to any sale of any such shares of Common Stock, shall be subject to potential cancellation, recoupment, rescission, payback or other action in accordance with the terms of the Company’s Clawback Policy, as it may be amended from time to time (the “Policy”). Optionee agrees and consents to the Company’s application, implementation and enforcement of (a) the Policy or any similar policy established by the Company that may apply to Optionee and (b) any provision of applicable law relating to cancellation, rescission, payback or recoupment of compensation, and expressly agrees that the Company may take such actions as are necessary to effectuate the Policy, any similar policy (as applicable to Optionee) or applicable law without further consent or action being required by Optionee. To the extent that the terms of this Agreement and the Policy or any similar policy conflict, then the terms of such policy shall prevail.

13. Severability. Any word, phrase, clause, sentence or other provision herein which violates or is prohibited by any applicable law, court decree or public policy shall be modified as necessary to avoid the violation or prohibition and so as to make this Agreement enforceable as fully as possible under applicable law, and if such cannot be so modified, the same shall be ineffective to the extent of such violation or prohibition without invalidating or affecting the remaining provisions herein.

14. Non-Waiver of Rights. The Company’s failure to enforce at any time any of the provisions of this Agreement or to require at any time performance by Optionee of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect either the validity of this Agreement, or any part hereof, or the right of the Company thereafter to enforce each and every provision in accordance with the terms of this Agreement.

15. Entire Agreement; Amendments. No modification, amendment or waiver of any of the provisions of this Agreement shall be effective unless in writing specifically referring hereto and signed by the parties hereto. This Agreement supersedes all prior agreements and understandings between Optionee and the Company to the extent that any such agreements or understandings conflict with the terms of this Agreement.

16. Assignment. This Agreement shall be freely assignable by the Company and shall inure to the benefit of, and be binding upon, the Company, its successors and assigns and/or any other entity which shall succeed to the business presently being conducted by the Company.

17. Governing Law. To the extent that Federal laws do not otherwise control, all determinations made, or actions taken pursuant hereto shall be governed by the laws of the State of New York, without regard to the conflict of laws rules thereof.

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed on its behalf by the undersigned officer pursuant to due authorization, and Optionee has signed this Agreement to evidence his acceptance of the option herein granted and of the terms hereof, all as of the date hereof.